Aims: Fibroscan ® is a non-invasive method to evaluate liver stiffness (LS), however, its accuracy in alcohol-related liver diseases (ALD) especially with respect to active or stopped alcohol drinking is largely unknown. We prospectively evaluated the LS changes in patients with ALD following alcohol withdrawal. Methods: Sixty-four patients were evaluated by FibroScan ® and lab tests at baseline and after 4 weeks of abstinence.
INTRODUCTION
Alcohol abuse is still a major health issue, with increasing diffusion in younger population. Alcohol-related liver disease (ALD) is the term used to describe changes within the liver that develop as a result of excess alcohol consumption. Included within this spectrum are hepatic steatosis (alcoholic fatty liver), alcoholic hepatitis, alcoholic cirrhosis and hepatocellular cancer (Mann et al., 2003) . Recently, it has been suggested that all people whose daily alcohol consumption exceeds 80 g (10 units) will eventually develop steatosis; 10-35% will develop alcoholic hepatitis, and approximately 10% will develop cirrhosis (Walsh and Alexander, 2000) . The occurrence of liver fibrosis is a crucial clinical landmark often leading to progressive irreversible changes within the liver and lifethreating complications. Liver biopsy is currently considered the gold standard for assessing hepatic fibrosis or cirrhosis, however, it is an invasive procedure with potential morbidity, sampling error and inter-observer variability. In addition, it is not feasible for prospective longitudinal evaluation of progression or regression of fibrosis, i.e. following alcohol abstinence. On the other hand, the detection of significant fibrosis in patients with alcohol abuse and its potential improvement could help the management and enhance the motivation of these subjects to cease alcohol intake.
Transient elastography (TE), assessed by FibroScan ® (Echosens, Paris, France) is a rapid and non-invasive test, widely validated especially in patients with C viral hepatitis, able to identify liver fibrosis as evaluated as liver stiffness (LS) (Sandrin et al., 2003) . Fibroscan ® , by using the technique of pulse elastography, quantifies the degree of stiffness which in turn nicely correlates with histological fibrotic score. However, TE is influenced by a number of variables such as ongoing liver necrosis and inflammation (Coco et al., 2007; Sagir et al., 2007; Arena et al., 2008) , the degree of steatosis (Lupşor et al., 2008) , cholestasis (Millonig et al., 2008) , and portal vein congestion (Colli et al., 2010; Millonig et al., 2010) .
A recent meta-analysis (Friedrich-Rust et al., 2008) has evaluated the accuracy of TE to predict the occurrence of significant fibrosis, severe fibrosis and cirrhosis in different liver diseases. The mean values of area under the curve of receiver operating characteristics were indeed 84%, 89%, and 94%, respectively. The experience (Castera et al., 2005; Ziol et al., 2005) in C and B chronic hepatitis has demonstrated a good correlation of liver stiffness with Metavir stage of fibrosis. In addition, TE has been demonstrated a useful tool to predict liver cirrhosis and portal hypertension related complications (Vizzutti et al., 2007) . Accordingly, in non-alcoholic steatohepatitis (NASH), TE is able to nicely evaluate the fibrotic stage, although the liver biopsy still remains the gold standard to disclose the inflammatory infiltrate (Yoneda et al., 2007) . A good correlation between TE and fibrotic stage has also been demonstrated in cholestatic diseases, such as primary biliary cirrhosis and sclerosing cholangitis (Corpechot et al., 2006) .
A number of studies have been performed to assess TE by FibroScan ® in patients with ALD (reviewed by Stevenson et al., 2012) . Fibroscan ® accurately assesses extensive fibrosis and cirrhosis (Nahon et al., 2008) , however the median LS value is higher than that observed in viral cirrhosis (Nguyen-Khac et al., 2008) . This might be explained by the different spatial distribution of alcoholic fibrosis (Michalak et al., 2003) , different degree of liver cell necrosis and inflammation. More importantly, the status of active drinker vs abstainer is an issue, as well as presumably the duration of alcohol consumption and withdrawal. Mueller et al. in 2010 firstly reported an evaluation of LS changes in a first exploratory cohort of 50 ALD patients and a further validation cohort of 101 patients. They found a decrease of LS after 1 week of abstinence strictly correlated to AST levels. In this study we aimed to prospectively evaluate the changes of LS in a cohort of ALD patients after 1 month of alcohol withdrawal, compared to baseline values. In addition, Fibroscan ® findings were correlated with laboratory and clinical parameters. We hypothesized that active alcohol intake might influence significantly LS and that the evaluation by Fibroscan ® during active drinking might overestimate the real value.
MATERIALS AND METHODS

Study population
Consecutive outpatients with alcohol abuse admitted at the Toxicology Unit of AOU Hospital Careggi or at Center for Alcohol In all patients a careful medical history was obtained with a structured questionnaire administered by one of the Author (GE), with special attention paid to the duration and characteristics of alcohol intake (type of alcohol, grams/day, previous attempt of abstinence). All patients received at baseline an abdominal ultrasonography to precisely evaluate liver morphology and rule out different diseases. Liver cirrhosis was suspected when at least two of the following criteria were present: (a) nodular aspect of the liver surface; (b) portal vein diameter > 12 mm; (c) collateral circulation and (d) hypertrophy of segment IV (quadrate lobe) (Di Lelilo et al., 1989) .
Laboratory
At baseline and at the 4 weeks follow-up FibroScan ® and blood chemistry including alanine aminostransferase (ALT), aspartate aminotransferase (AST), gamma glutamyltransferase (γGT), cholesterol and ferritin were evaluated. At the follow-up adherence to alcohol abstinence was asked, and in case of doubt the urinary ethilglucuronide was evaluated.
Liver stiffnes (LS) measured by transient elastography (TE) with Fibroscan ® FibroScan ® consists of a 5-MHz ultrasound transducer probe mounted on the axis of a vibrator: the operator was one of the authors (FP) who had previously performed more than 500 determinations in patients with liver disease. The tip of the probe transducers was placed on the skin between the rib bones and the level of the right lobe of the liver. The measurement depth was between 25 and 65 mm below the skin surface. The median value of 10 successful acquisitions after an overnight fast, expressed in kilopascals (kPa), was considered as a measure of LS. As previously described, 10 successful acquisitions with a success rate of at least 80% were considered as representative (Arena et al. 2008) , and a value ≥ 7 kPa (Castera et al. 2008 ) was considered as abnormal. Given the large inter-subjects variability of kPa data, we grouped the LS findings as previously suggested (Castera et al. 2008) in different stages as follows: normal (Normal Liver Stiffness = 0, LS0) = <5.5 kPa; slight increase (LS1) = 5.6-7 kPa; significant increase (LS2) = 7.1-9.5 kPa; moderate increase (LS3) = 9.6-12.5 kPa; severe increase (LS4) = >12.5 kPa.
Statistical analysis
Qualitative variables were compared using χ2 and Fishers exact test as appropriated, while quantitative variables were compared by Student t test and non-parametric Wilcoxon test when appropriate.
RESULTS
Study population
Sixty-six consecutive patients were enrolled from February 2010 to March 2011, however, in 2 out of 66 patients the FibroScan ® evaluations failed and were excluded from the study. Main blood chemistry, clinical parameters and FibroScan ® findings of the enrolled patients are summarized in Table 1 . More specifically, 22 subjects were females, 42 males, with a mean age of 47 years (range 29-71 years) and a mean body mass index (BMI) of 22.9 kg/m 2 (range 16-32 kg/m 2 ). The mean alcohol intake was 253 g/day (range 40-400 g/day) with a mean duration of abuse of 7 years (range 1-30 years). Fifteen patients were overweight, with a maximum BMI of 30. Fifty-four patients (84%) had abnormal liver function tests, and 20 had liver steatosis at ultrasonography. Twenty-two out of the 64 patients (34%) had a stiffness value greater than 7 kPa at baseline (T0). By evaluating the LS stages, 23, 19, 8, 3 and 11 patients had a LS0, LS1, LS2, LS3 and LS4, respectively (values ≤5.5 kPa, 5.6-7 kPa, 7.1-9.5 kPa, 9.6-12.5 kPa, >12.5 kPa).
Follow-up
The main changes of parameters compared to baseline are summarized in Table 2 . At 4 weeks, only 50 patients (78%) were available and performed blood chemistry and FibroScan ® evaluation (Fig. 1) ; in addition, 10 out 50 declared non-compliance with alcohol abstinence (Table 2) . Sixteen still had a significant (≥7 kPa) high LS, and 27 had abnormal liver function tests. Within the group of subjects with abnormal LS, 12 out of 16 (75%) had abnormal transaminases compared to 15 out 34 patients with normal LS (p < 0.04). By evaluating the group of 40 patients with adherence to alcohol abstinence, 13 (32.5%) had still a LS ≥ 7 kPa, and 18 (45%) still had abnormal transaminase values. Of note, 33 out of 40 patients (83%) with alcohol abstinence at T1 reduced the LS (mean reduction −2.6 ± 5.5 kPa); in addition, 12 out 13 (92%) patients with baseline LS ≥ 7 kPa had a significant (at least 20%) reduction compared to baseline values (11.7 ± 12.3 vs 18.8 ± 14.1 kPa; P = 0.008). This reduction was significantly higher compared to that observed in patients with baseline level of LS < 7 kPa who displayed a mean reduction of only 0.4 ± 0.6 kPa (P = 0.01) ( Table 3 ). In addition, subjects abstinent and with normalization of transaminases had a significant reduction of the mean LS compared to baseline values (5.9 ± 2.1 vs 8.9 ± 5.7 kPa) (P = 0.03).
By evaluating the LS values, 16 out of 40 abstinent reduced their LS stages compared to none of the active drinkers (P = 0.01) (Fig. 2) , with a significant reduction compared to baseline (0.93 ± 1.2 vs 1.38 ± 1.4)(P = 0.02).
Given the high frequency of reduction of LS in abstinent compared to drinkers, we calculated the predictive value of a reduction of LS with respect to drinker status; the positive predictive value (PPV) was 0.92, while the negative predictive value (NPV) was only 0.5. Final follow-up (24 weeks): being most of the patients still in active follow-up, although not initially specified in the study protocol, we asked to repeat the lab tests and Fibroscan. Only 27 patients accepted; 22 were still abstinent while the remaining 5 relapsed to drink alcohol. Only 4 out 22 abstinent (18%) had a LS ≥ 7 kPa and all except one had normal transaminases. Four out of 22 abstinent (18%) further reduced the LS compared to T0, with a mean of 5.1 ± 6.7 kPa (P = 0.03 vs baseline). In addition the abstinent with baseline LS ≥ 7 kPa had a mean LS of mean 6.5 ± 4 kPa (vs 17.6 ± 9.8 at baseline) (P = 0.005). By analyzing the LS values of patients with abnormal transaminases at the baseline, all patients (18 out 18) had reduced the LS to a mean of 5.4 ± 3.1 kPa vs 11.5 ± 8.3 kPa at the baseline (P = 0.006) ( Table 3) .
By evaluating the changes of LS, 13 out of 22 abstinent further reduced the LS stages, compared to none out of the five drinkers (P = 0.04) (Fig. 3) . The mean LS stages were significantly reduced in abstinent (1.1 ± 1.3 vs 1.6 ± 1.6)(P = 0.006) and almost unchanged in drinkers (0.9 ± 0.7 vs 0.7 ± 0.8).
DISCUSSION
Alcohol abuse is a common social problem leading to ALD and its complications. A widely recognized landmark of disease progression is the occurrence of liver fibrosis which is frequently investigated by Fibroscan ® . However, is largely unknown to which extent the abstinence and its duration might influence LS and its changes over time.
In this study we aimed to prospectively monitor 64 ALD patients who accepted to cease alcohol by TE and blood chemistry. At baseline one third of patients had a significant increase (>7 kPa) of LS, and 84% had abnormal transaminases. At 1 month, 32.5% of abstinent (n = 40) had still a LS > 7 kPa, but 16 out of 40 reduced their LS stages compared to none of the drinkers (P = 0.01). In contrast, almost all drinkers (n = 10) increased the LS compared to baseline. The LS reduction was significantly greater in patients with higher (>7 kPa) baseline level and increased transaminases. Of note, 27 patients were further investigated after 6 months; 13 out of 14 patients who stopped the alcohol with baseline LS > 7 kPa further improved.
Several studies (Melin et al., 2005; Nahon et al., 2008; Kim et al., 2009; Janssens et al., 2010; Mueller et al., 2010 Mueller et al., , 2015 Pavlov et al., 2015; Thiele et al., 2016) have assessed the accuracy of FibroScan ® to identify moderate-to-severe fibrosis and cirrhosis in patients with known or suspected ALD. In the study by Nahon et al. (2008) , by using a threshold score of 11.6, FibroScan ® identified severe (F3-F4) fibrosis with a sensitivity of 87% (95% CI 80-93), and a specificity of 89% (95% CI 76-96). A recent review of the Cochrane (Pavlov et al. 2015) reported five retrospective and nine prospective cohort studies with 834 participants. The main conclusion was that TE may be used as a diagnostic method to rule out liver cirrhosis (F4) and severe fibrosis (F3 or worse), however, the best cut-off values in people with ALD is not established yet. Thiele et al. (2016) , in a prospective study of 199 patients with alcohol abuse, reported that TE identified with high accuracy (AUC ≥ 0.92) significant fibrosis and cirrhosis proven at histology. Mueller et al. (2015) evaluated TE in a large cohort of patients with chronic viral hepatitis C and ALD; they found that LS cut-off values for histology proven significant fibrosis and cirrhosis are influenced by abnormal transaminases. Unfortunately, data on changes of LS following abstinence are few. Mueller et al. (2010) reported the changes of LS in an exploratory cohort of 50 ALD patients and a validation cohort of 101 patients. The decrease over time of LS strictly correlated to AST levels, with no further improvement with AST below 100 U/L. However, the re-evaluation of Fibroscan ® was performed following only 1 week of abstinence, thus potentially underestimating the LS changes. Gelsi et al. (2011) 
T1 vs T0
Changes in subjects with kPa > 7 at baseline 11.7 ± 12.3 vs 18.8 ± 14.1 0.008 Changes of kPa in patients with elevated transaminases at baseline 5.9 ± 2.1 vs 8.9 ± 5.7 0.03 Delta kPa from baseline −2.6 ± 5.5 2.2 ± 3.6 0.004 Changes of liver stiffness stages 0.93 ± 1.2 vs 1.38 ± 1.4* 1.9 ± 1.4 vs 1.5 ± 1.5 *0.02 T2 vs T0 Changes in subjects with kPa > 7 baseline 6.5 ± 4 vs 17.5 ± 9.8 0.005 Changes of kPa in patients with elevated transaminases at baseline 5.4 ± 3.1 vs 11.5 ± 8.3 0.006 Delta kPa from baseline −5.4 ± 8 0.7 ± 3.5 0.005 Changes of liver stiffness stages 1.1 ± 1.3 vs 1.6 ± 1.6* 0.9 ± 0.7 vs 0.7 ± 0.8 *0.006 *, statistical significance of difference vs baseline values.
follow-up of 32.5 weeks. At the final evaluation only 13 (35%) were abstinent. TE decreased significantly during follow-up in 85% of abstinent. Lahmek et al. (2014) reported 30 patients with ALD who received a second TE in a median of 21 days after. The decrease in liver stiffness was found significant only for patients with recent alcohol ingestion.
The main findings of our study are the following: (a) after 1 month of abstinence there is a significant decrease of LS as evaluated by TE, paralleled by normalization of transaminases; (b) the Fibroscan ® might overestimate LS in patients during active drinking and (c) in active or relapsing drinkers LS remains stable or increases. The rapid decrease of LS (−25%) during abstinence, especially observed in patients with more elevated (>7 kPa) baseline level (−38%), suggests that changes of LS reflects an easily reversible condition rather than a true regression of fibrosis. The greater reduction of LS in patients with abnormal transaminases at the baseline might suggest that reduced cytolysis and inflammatory infiltrate could be one possible explanation. However, the LS was clearly reduced also in patients with normal transaminases at the baseline. In addition, the greater reduction of LS in patients with higher baseline level strongly suggests a rapidly reversible phenomenon. Further information could be probably obtained by sequential evaluation of changes of liver steatosis by ultrasonography.
The finding that LS remains stable or increases in active drinkers might both enhance the awareness of non-compliance and enhance the adherence to abstinence program, however, the cost of Fibroscan ® repetition is an issue.
Our study has a number of limitations: only 50 out of the initial 64 patients were available at follow-up, and 10 out of 50 did not stop completely the alcohol intake. Notwithstanding, this is the largest study with at least one month of evaluation after abstinence. In addition, we had also the opportunity to re-evaluate 27 of initial 64 patients at 6 months. However, it does not seem that such prolonged follow-up with Fibroscan ® is clinically meaningful. Furthermore, no other objective parameters were used to evaluate and monitor liver fibrosis and steatosis. Nevertheless, these drawbacks are difficult to overcome for ethical (i.e. liver biopsy) and practical (poor compliance) reasons.
In summary, TE evaluated by Fibroscan ® in ALD patients while actively drinking presumably measures the composite alcoholinduced liver damage, and might overestimate the 'real fibrosis'. After 1 month of abstinence, the LS is dramatically reduced in abstinent, especially when values are greater than 7 kPa and transaminase elevated at baseline. The improvement of LS accurately predicts adherence to abstinence program.
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